This compound is primarily used in combination with trifluridine as a pharmaceutical treatment for metastatic colorectal cancer. It works by inhibiting the enzyme thymidine phosphorylase, which helps to increase the bioavailability and efficacy of trifluridine, a nucleoside metabolic inhibitor. This combination therapy is particularly beneficial for patients who have previously undergone other forms of chemotherapy without success. Additionally, it is being researched for its potential applications in treating other types of cancers, demonstrating its versatility in oncology treatments.